FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20

0287
0.5
(

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Title of Security (Instr. 3) 2. Tr					_ M	ER	IT M	IEDIC		<u>/SŤ</u>	Symbol EMS IN	С[мм	SI (Ch	Directo Officer below)	Director Officer (give title			vner specify
(Street)	II		84095		_ 03	/12/	2021				I (Month/Day	//Year)	6. I Lin	ndividual or J e) X Form f	loint/Group	Filing Repo		plicable n
(City)	(S													Persor	1	e man	Опе кероп	ung
			2. Trans Date (Month	saction	ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		(A) or	5. Amou Securition	nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			
Common	Stock, No	Par Value		03/1	2/202 1	1			М		25,000	A	\$12.0	6 32	,343		D	
Common Stock, No Par Value			03/1	03/12/2021						25,000	D	\$59.58	³⁽¹⁾ 7,	343		D		
Common	Stock, No	Par Value												16,2	83.343		I	By 401(k) plan ⁽²⁾
			Table II								osed of, convertib			Owned				
Derivative Conversion Date Execution Date, Tr Security or Exercise (Month/Day/Year) if any				4. Transa Code (8)				6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 a	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares					
Non- qualified stock options (right to buy)	\$12.06	03/12/2021			M			25,000	10/04/20	15 ⁽³⁾	10/04/2021	Common Stock	25,000	\$0	0		D	
Non- qualified stock options (right to buy)	\$17.27								02/13/20	16 ⁽⁴⁾	02/13/2022	Common Stock	20,000		20,00	0	D	
Non- qualified stock options (right to buy)	\$16.05								01/28/20	17 ⁽⁵⁾	01/28/2023	Common stock	20,000		20,00	0	D	
Non- qualified stock options (right to buy)	\$28.2								04/14/20	18 ⁽⁶⁾	04/14/2024	Common Stock	50,000		50,00	0	D	
Non- qualified stock options (right to buy)	\$44.8								03/02/20	19 ⁽⁷⁾	03/02/2025	Common Stock	40,000		40,00	0	D	
Non- qualified stock options (right to buy)	\$55.73								03/01/20	20 ⁽⁸⁾	03/01/2026	Common Stock	30,000		30,00	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		Transaction of Code (Instr. Derivative			6. Date Exerci Expiration Dat (Month/Day/Ye	e	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- qualified stock options (right to buy)	\$37.71							02/26/2021 ⁽⁹⁾	02/26/2027	Common Stock	16,722		16,722	D	

Explanation of Responses:

- 1. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$59.93 to \$59.50, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 2. Represents plan holdings as of 02/26/2021.
- 3. Become exercisable in equal annual installments of 20% commencing 10/04/2015.
- 4. Become exercisable in equal annual installments of 20% commencing 02/13/2016.
- $5.\ Become \ exercisable \ in \ equal \ annual \ installments \ of \ 20\% \ commencing \ 01/28/2017.$
- 6. Become exercisable in equal annual installments of 20% commencing 04/14/2018.
- 7. Become exercisable in equal annual installments of 20% commencing 03/02/2019.
- 8. Become exercisable in equal annual installments of 20% commencing 03/01/2020.
- 9. Become exercisable in equal annual installments of 25% commencing 02/26/2021.

/s/ Brian G. Lloyd, Attorney-in-03/16/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.